NAPROSYN AND ANAPROX FIRST QUARTER SALES HIT $137 MIL., AS NSAIDS MAKE UP TWO-THIRDS OF SYNTEX DRUG VOLUME; MEDICINE SHOPPE FISCAL 1986 PROFITS UP
Executive Summary
Worldwide sales of Naprosyn (naproxen) and Anaprox (naproxen sodium) increased 7% to $137.3 mil. during the first quarter, Syntex reported. Together the two NSAIDs made up 65% of the company's $211.5 mil. total pharmaceutical sales and over half of its $263 mil. corporate volume. Much of the increase took place outside the U.S, however, where combined sales of Naprosyn and Anaprox jumped 20% to $43 mil. Sales in the larger U.S. market increased only 2% to $94 mil. The company attributed the sales growth outside the U.S. to a weakening dollar and higher volume. For the three months ended Oct. 31, Syntex reported a 31% increase in net earnings, from $49 mil. in the first quarter of fiscal 1986 to $64 mil. "Our record earnings performance was made possible by increased pharmaceutical sales; good growth in our diagnostics business; and improved performance in our animal health business," Syntex Chairman Albert Bowers, PhD, noted. The earnings jump came on a 7% increase in total corporate sales. Syntex also reported that R&D spending was approximately 11% higher than in the same quarter of fiscal 1986. The company said that for all of fiscal 1987 it plans to increase R&D spending roughly 20%. Medicine Shoppe showed strong sales and earnings growth for both the quarter and year ended Sept. 30. Three-month volume was up nearly 27% to $4.7 mil., while net earnings made a similar move, rising 26% to just over $1 mil. For all of fiscal 1986, volume and profits increased in excess of 20%. Year-end sales were up 22.3% to nearly $17 mil. and net earnings jumped almost 21% to $3.6 mil. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth